Best objective response. NSCLC: non–small cell lung cancer; PD: progressive disease; SD: stable disease. Note: Waterfall plot of patients treated with Helixor-M and had follow-up scans after baseline to evaluate tumor response (N = 17). Their best tumor response is shown as the percentage change from baseline in the longest diameter of the target lesion. The numbers in parentheses are the number of prior systemic therapies (including targeted therapy, hormonal therapy, immunotherapy, or chemotherapy), the number of prior radiation treatments, and the number of surgeries.